Response to neo-adjuvant chemotherapy for colorectal liver metastasis of cancer: a key to improving the survival?

R. Bertani Chiappa, e., r. Biffi, u. peace

Liver Resection in colorectal cancer metastatic disease offers the best chance in cases selected for the long-term survival. Intravenous pyelogram (NACT) Chemotherapy was supported in some cases initially deemed irresectable, with few reports the effectiveness of this strategy and the influence of chemoresponsiveness on the outcome of radical liver resection. Methodology: Between December 1995 and 27 patients with colorectal liver metastases, May 2005 (7 20 females, males, mean age: 58 8 years; range: 40-75) were treated with chemotherapy neoadjuvant chemotherapy.You performed a survival analysis of 7 years. Chemotherapy included mainly 5-fluorouracil, leucovorin and Oxaliplatin and irinotecan to a median of 8 courses.

Sixteen patients (59%) had synchronous and 11 metastasis metachronous (41%). during the regression of cancer chemotherapy pre that occurred in 10 cases (37%); stable disease (SD) in a further 10 patients (37%) and the progressive disease (PD) developed in 7 cases (26%). Year 5 General survival for NACT responders was 64% and only 15% for non-responders (p = 0.044).

The response to chemotherapy is likely to be a significant prognostic factor affecting the survival after liver resection for care.

Volume: 1 article number: 58 DOI: 10.3332/ecancer. 2008 58 received: 20/08/2007 published: 16/10/2007

To view this article in its entirety, you must first sign in or register.

View the original article here